Breast Imaging Flashcards
Imaging breast cancer: Key facts
Breast cancer is the most common female cancer in the United States. The average woman has a one in eight chance of being diagnosed with breast cancer during her lifetime.
Mammography is the first-line tool for detection of breast cancer; however, the sensitivity of screening mammography for detecting cancer has been estimated at between 68% and 90%, with the lower range of this scale true for mammographically dense tissues. Of note, diagnostic mammography (used ot evalute a patient with signs or symptoms suggestive of breast cancer) has a higher sensitivity, up to 93%.
Ultrasound is a critical adjunct imaging modality to mammography, but ultrasound is not used for screening. The indications for performing breast ultrasound are characterization of palpable abnormalities, further characterization of mammographic findings, first-line evaluation of a breast abnormality in a young (under age 30), pregnant, or lactating woman, guidance for interventional procedures, and evaluation of breast implants.
MRI is an established breast imaging modality. The indications for breast MRI include screening in high-risk patients (greater than 20% lifetime risk of developing breast cancer), evaluation of extent of disease in a paitent newly diagnosed with breast cancer, evaluation of neoadjuvant chemotherapy response, assessment for residual disease after positive surgical margins, evaluation for tumor recurrence, and evaluation for occult breast cancer in a patient with axillary metastases.
The pathway of invasive ductal breast cancer progression
The current understanding of progression to ductal breast cancer is a multi-step transformation from normal cells to flat epithelial atypia (FEA), to atypical ductal hyperplasia (ADH), to ductal carcinoma in situ (DCIS), to invasive ductal carcinoma (IDC).
ADH is intraductal proliferation with cytological atypia but without the definitive architectural or cytological abnormalities of DCIS. FEA is related to ADH and is characterized by abnormal ductal cells. FEA and ADH are considered non-obligatory precursor lesions; that is, the presence of ADH or FEA is an indicator of a higher risk of developing breast cancer, rather than an obligatory precursor towards invasive cancer.
If a core biopsy shows FEA, excisional biopsy is advocated by several authors. 14% of patients with a core needle biopsy of FEA will be upstaged to DCIS or invasive carcinoma upon surgical excision.
A core biopsy with pathology of atypical ductal hyperplasia (ADH) is followed by surgical excision. Approximately 18% of ADH diagnosed by core needle biopsy will be upstaged to either invasive carcinoma or DCIS upon surgical excision.
Ductal carcinoma in situ (DCIS) is most often occult cancer detected mammographically and is treated surgically. Breast imaging plays an essential role in the diagnosis of DCIS as DCIS is typically asymptomatic and nonpalpable. Histologically, DCIS represents carcinoma contained within the duct, with an intact basement membrane surrounding the duct. Between 30-50% of patients with DCIS will develop invasive carcinoma within 10 years. Approximately 43% of DCIS diagnosed by ultrasound-guided core needle biopsy is upstaged to invasive carcinoma upon surgical excision.
Risk factors for developing breast cancer
The two most important risk factors for breast cancer are female sex and advancing age. Other important risk factors for breast cancer include:
Inherited BRCA1 or BRCA2 mutation. Women with an inherited mutation have greater than 50% chance (some believe as high as 80% chance) of developing breast cancer by age 80.
First degree relative with breast cancer. In contrast, a non-first degree relative with postmenopausal breast cancer is not considered an increased risk.
Prior chest radiation for Hodgkin or non-Hodgkin lymphoma.
Long-term estrogen exposure, such as early menarche, late menopause, late first pregnancy, nulliparity, or obesity (through increased estrogen production by adipocytes).
Prior biopsy result of a high risk lesion in the lobular neoplasia spectrum, including atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS). Unlike ADH and FEA, which are high risk lesions in the ductal neoplasia spectrum, the high risk lesions in the lobular neoplasia spectrum are not treated with surgical excision. ALH and LCIS arise from the terminal duct lobule, can be distributed diffusely throughout the breast, and are considered a marker of increased risk rather than a precursor to invasive carcinoma. Women with LCIS have a 30% risk of developing invasive cancer (usually invasive ductal), which may occur in either breast.
Special histologic subtypes of invasive ductal carcinoma
Breast cancer is a diverse spectrum of disease with varying histopathology and prognosis.
The most common subtype of breast cancer is invasive ductal carcinoma (IDC), representing 70-80% of cases. It often presents as a palpable mass, usually with a classic mammographic appearance of a spiculated mass, architectural distortion, and pleomorphic calcifications.
Combined, a number of less common subtypes make up less than 10% of all breast cancers. In general, these special subtypes have better prognosis than invasive ductal carcinoma not otherwise specified (IDC NOS).
Special subtypes of ductal breast cancer
Tubular carcinoma is a low grade cancer that typically presents as a small spiculated mass. Prognosis is better than IDC NOS. It may be difficult for the pathologist to distinguish between radial scars/complex sclerosing lesions and tubular carcinoma, and it is thought that radial scar may be a precursor to tubular carcinoma.
Mucinous carcinoma (synonyms: colloid carcinoma, mucoid carcinoma, and gelatinous carcinoma) typically is a low-density circumscribed mass that can mimic a fibroadenoma on ultrasound. On MRI mucinous carcinoma usually appears hyperintense on T2-weighted images.
Medullary carcinoma is a rare variant of breast cancer, typically seen in younger women, often with BRCA1 mutation. Medullary carcinoma is locally aggressive, but has a better prognosis than IDC NOS.
Papillary carcinoma is the malignant form of an intraductal papilloma.
Adenoid cystic carcinoma is a very rare breast cancer that presents as a palpable firm mass. Prognosis is excellent with complete resection.
Invasive lobular carcinoma
Invasive lobular carcinoma comprises approximately 5-10% of breast cancer cases. Compared to invasive ductal carcinoma, invasive lobular is typically much more difficult to diagnose mammographically and clinically due to its tendency to spread through the breast tissue without forming a discrete mass.
Invasive lobular carcinoma presents an imaging challenge due to its elusive appearance, which ranges from a one-view asymmetry to architectural distortion to a spiculated mass.
Inflammatory carcinoma
Inflammatory carcinoma represents tumor invasion of dermal lymphatics.
Clinically, inflammatory carcinoma presents with breast erythema, edema, and firmness.
On mammography, the affected breast is larger and denser, with trabecular thickening and skin thickening. Occasionally, no discrete mass will be apparent. The primary differential consideration is a breast abscess; however, the clinical setting and exam will usually be able to differentiate.
Paget disease of the nipple
Paget disease of the nipple is a form of DCIS that infiltrates the epidermis of the nipple.
Clinically, Paget disease of the nipple presents with erythema, ulceration, and eczematoid changes of the nipple.
Breast cancer prognosis
In non-metastatic breast cancer, axillary lymph node status is the most important prognostic factor, with the absence of nodal involvement offering the highest likelihood of cure. Similarly, survival is progressively worse with increased number of involved axillary nodes. The primary method to detect axillary involvement is a surgical sentinel lymph node biopsy, with a sensitivity of 93%. Sentinel lymph node biopsy is not routinely performed for DCIS unless necrosis or microinvasive disease is present. Surgical axillary lymph node dissection has a 99% sensitivity for detecting lymph node involvement. Lymph node diessection is performed if the sentinel lymph node is positive or not identified. Women with positive lymph nodes or with large tumors may benefit from neoadjuvant chemotherapy.
The presence of tumor receptors affects prognosis. Patients with estrogen receptor (ER) and progesterone receptor (PR) positive tumors have longer disease free survival. Cancers with HER2/neu overexpression may respond to the monoclonal antibody trastuzamab (brand name Herceptin) or tyrosine kinase inhibitors such as lapatnib.
Triple-negative cancers are ER, PR, and HER2/neu negative, are biologically aggressive, and portend a poor prognosis. Triple negative cancers are seen most often in patients with BRCA1 mutation. It has been suggested that triple-negative cancers may show benign featrues on mammography and ultrasound despite their aggressive nature. They are often round with smooth margins, without spiculations and calcifications, and are located posterioly in the breast.
There are several histologic subtypes of DCIS, with varying prognosis. A key factor to determine the prognosis of DCIS is the presence of necrosis. DCIS without necrosis (cribiform and micropapillary subtypes) is lower grade. Sentinel node evaluation is usually not indicated. DCIS with necrosis (poorly differentiated, comedo, and large-cell subtypes) is higher grade. On mammography, the typical manifestation of high-grade DCIS is pleomorphic or fine linear branching calcifications, which are caused by calcfication of necrotic debris in the duct lumen. Sentinel lymph node biopsy is often performed for high-grade DCIS.
Fibrocystic change (Cyclical and proliferative breast disease)
Fibrocystic change is an essentially normal pattern of breast physiology.
Clinically, fibrocystic change presents as cyclical breast pain, sometimes with a palpable lump. Fibrocystic change is almost always seen in pre-menopausal women.
Imaging findings are not specific and fibrocystic change is not ever a diagnosis made on imaging. Its only significance is that it may cause certain imaging abnormalities that instigate further workup, such as cysts and calcifications.
Sclerosing adenosis
Sclerosing adenosis is a benign proliferative lesion caused by lobular hyperplasia and formation of fibrous tissue that distorts the glandular elements.
Similar to fibrocystic change, the imaging importance of sclerosing adenosis is that is can mimic DCIS with microcalcifications.
Mastitis
Mastitis is infection of the breastl, most commonly by Staphylococcus aureus. It is typically seen in nursing mothers (called lactational or puerperal mastitis) or in diabetic patients.
Clinically, mastistis presents with breast pain, induration, and erythema.
Imaging is usually not performed, but mammography or ultrasound can show focal or diffuse skin thickening, breast edema, and adenopathy.
Treatment is antbiotics. If inadequately treated, mastitis can develop into a breast abscess.
Breast abscess
A breast abscess is a walled-off purulent collection, typiaclly from S. aureus.
Clinically, breast abscess appears as an irregular mass, which can mimic carcinoma based on imaging appearance alone.
Ultrasound shows an ill-defined mass with heterogenous echoes and irregular margins. An internal fluid level may be present. The primary differential consideration is inflammatory carcinoma; however, the clinical setting and exam will usually be able to differentiate.
Treatment is ultrasound-guided aspiration in addition to antibiotics.
Granulomatous mastitis
Granulomatous mastitis is a rare idiopathic noninfectious cause of breast inflammation that occurs in young women after childbirth.
Granulomatous mastitis may be associated with breast feeding or oral contraceptives.
The mammographic and sonographic features of granulomatous mastitis may mimic breast cancer and biopsy is usually warranted.
Periductal mastitis
Periductal mastitis, also known as plasma cell mastitis, is caused by the irritating contents of intraductal lipids. It is seen in post-menopausal women and produces the classic mammographic appearance of large, rod-like secretory calcifications.
Diabetic mastopathy
Diabetic mastopathy is a sequela of long-term insulin-dependent diabetes. An autoimmune reaction to matrix proteins from chronic hyperglycemia causes a firm and sometimes painful mass.
On mammography, diabetic mastopathy can appear as an ill-defined, asymmetric density without microcalcifications.
Ultrasound typically shows a hypoechoic mass or regional acoustic shadowing, mimicking the appearance of a scirrhous breast cancer.
Because the mammographic and sonographic appearanc can mimic breast cancer, core biopsy is required.
Mondor disease
Mondor disease is thrombophlebitis of a superficial vein of the breast, most commonly the thoracoepigastric vein.
Clinically, Mondor disease presents with pain and tenderness in the region of the thrombosed vein. A cordlike, elongated superficial mass may be present.
Ultrasound shows a dilated, “bead-like” tubular structure with no flow on color Doppler.
Screening Mammography
The goal of screening mammography is to detect pre-clinical breast cancer in asymptomatic women. Screening mamography detects 2 to 8 cancers per 1,000 women screened.
Since 1990, the mortality from breast cancer has been steadily declining at a rate of approximately 2.2% per year, thought to be due to improvements in adjuvant therapy and screening mammography. The current American Cancer Society guidelines (2010) for screening mammography recommend annual screening for women over age 40 (or 10 years younger than a first degree relative with breast cancer).
In 2009, the US Preventative Services Task Force (USPSTF) reclassified the evidence for screening of women age 40-49 from a class B (moderately strong evidence) to a class C (based on individual factors) recommendation, and also recommend reducing the screening interval between ages 50-74 to biannually. This has caused considerable controversy.
Statistical models show that screening starting at age 40 (instead of age 50) would avert one additional death from breast cancer for every 1,000 women screened, with a resultant average of 33 life-years gained per 1,000 women screened.
The potential concerns for mammographic screening include a very small risk of inducing breast cancer from radiation exposure, and risks of over-diagnosis including anxiety from false positives and unnecessary biopsies.
No single radomized trial has shown a mortality reduction due to mammographic screening in women age 40-49; however, several meta-analyses have shown a reduction in breast cancer specific mortality of 15-20%.
It is generally accepted that women at 50-69 benefit from annual screening mammography, with a 14-30% reduction in breast-cancer mortality in those women participating in screening mammography.
There are no strong data to support screening mammography in women over age 70.
Routine screening mammographic views
The two standard mammographic views are cranio-caudal (CC) and medial-lateral-oblique (MLO).
The cranio-caudal (CC) image plane is transaxial.
The medial-lateral-oblique (MLO) image plane is approximately 45 to 60 degrees from the axial plane, paralleling the course of the pectoralis muscle heading into the axilla. The MLO view is ideal for screening, as it captures most of the breast tissue in a single view. Note that the superior-medial breast tissue may be excluded on the MLO view.
At the technologists discretion, additional views may be performed to iamge all of the glandular tissue: Cleavage view (CV) images the medial breast of tissue of both breasts. The exaggerated CC (XCC) view pulls either lateral or medial tissue into the imaging detector.

Online and Offline screening
Typically, most scrrening mammography is interpreted offline, where a batch of exams are reviewed in bulk some time after the films were taken.
Online screening, where women have mammography performed and then wait ot get a final report from the radiologist, leads to more imaging being performed and more false positives, with the same cancer detection rate.
In contrast to screening mammography, all diagnostic mamography is performed “online” as a monitored exam with the patient staying for all possible imaging and the final results/recommendations before leaving.
Indications for diagnostic mammography
Diagnostic mammography is usually performed for a breast problem (pain, lump, skin thickening, nipple discharge).
Other indications of diagnostic mammography include annual mammography in an asymptomatic women with a past history of breast cancer, short interval follow-up (following of BI-RADS 3 lesions), and evaluation of an abnormality found on screening mammogram.
Diagnostic mammography procedure
Any mammographic abnormality is first localized in three dimensional space, then worked-up with special problem-solving techniques.
Often, ultrasound is added at the radiologist’s discretion.
Each patient waits until all imaging is completed before receiving a summary of the final interpretation and recommendations from the radiologist.
Evaluate image quality and adequacy
The first step in evaluating a mammogram is to determine if the study is tecnhically adequate.
There should be adequate tissue imaged on both the CC and MLO views. The posterior nipple line is a line drawn from the posterior nipple to teh pectoralis muscle - or edge of the film on the CC view if the pectoralis is not visualized. The posterior nipple lines drawn on the CC and MLO views should be within 1 cm of each other.
The image must be free from blur and artifacts. The trabeculaeshoudl be sharp; if blur is present, then benign calcifications can be mistaken for suspicious amorphous calcifications, and subtle calcifications can be missed entirely.
The nipple of each breast should be in profile in at least one view.
Each projection should be globally compared side-to-side to evaluate for symmetry.
Each image should be carefully evaluated for signs of malignancy. The mammographic signs of malignancy are mass, calcification, architectural distortion, and asymmetry. Calcifications are best viewed at 1:1 or higher magnification, while architectural distortion is best seen when the whole breast is visualized.
When viewing a digital mammogram, every portion of the image should be carefully evaluated at 1:1 zoom.
Even if a study appears unremarkable at first glance, comparison to prior exams can often reveal a subtle progressive change. For instance, an apparently normal island of parenchymal tissue may be slowly growing and represent malignancy.
In general, it is best to carefully compare the previous exam from at least two years prior, to appreciated slowly growing changes.







